MedTech Strategist

In a fireside chat at BioFuture, The Feinstein Institutes CEO Kevin J. Tracey was optimistic that bioelectronics, and vagus nerve stimulation specifically, has the potential to extend the healthy lifespan on a population-wide basis, much the way better control of infectious disease led to major gains in life expectancy in the last century. By Senior Writer Wendy Diller: https://bit.ly/3BsP7mh #innovation #medtech #bioelectronics #vagusnervestimulation #medicaldevices

Thanks to the influx of AI, machine learning, machine vision, and other technological advances in data analysis, the infertility industry is experiencing a much-needed overhaul.     As in other clinical and medical device segments, technology can help improve clinical decision-making, automate labor-intensive workflows, and provide consistency to the expertise-dependent tasks with which fertility care is rife. In this first part of a series of articles on AI’s role in assisted reproduction, we interview Mylene Yao, M.D., CEO and Co-founder of Univfy, about its machine-learning tool for IVF prognostication to help guide patient decision-making: https://bit.ly/4iFS1ol #medtech #businessstrategies #medtechinnovation #innovation #medicaldevices #dataanalysis #AI #machinelearning #fertilitycare

Improving critical care through innovations like REBOA is essential for better patient outcomes. See how these advancements are reducing risks and saving lives. #medtechinnovation

Point-of-care testing is a game-changer for accessibility and patient outcomes. Excited to see how Medidata Solutions is driving #innovation to make diagnostics faster and more efficient. Gina Bransley provides great insights in her new article with MedTech Strategist!

Why are exits extremely limited with the nonexistent IPO market? The big companies also are hesitant to spend money on business development (see Figure 2 below). M&A activity increased slightly in 2023 from 2022 but remained well below 2021 levels, and private M&A activity has been slow to date in 2024 as well. Without an IPO window, acquirers are cautious about paying premiums for early-stage companies, instead looking to expand their markets with commercial-stage tuck-in acquisitions. While new technologies are flourishing in the diagnostics industry, and pharma is finally realizing the importance of diagnostics to the success of its drugs, at the R&D and commercial levels, financing start-ups fueling that innovation is getting tougher: https://bit.ly/41fsT1q Source: HSBC #innovation #medtech #medicaldevices #m&a #businessdevelopment

What are 3 tangible benefits of presenting your startup at MedTech Strategist Innovation Summit in Dublin, Ireland?   1. Access to Global Investment and Strategic Partners: Presenting companies are pre-screened, ensuring high-quality engagement with a global audience of investors, venture capitalists, and strategic partners actively seeking innovative medical device opportunities. 2. Tailored Networking and Business Partnering Opportunities: The conference offers dedicated private breakout rooms for one-on-one meetings, enabling presenters to directly connect with interested parties and advance partnerships efficiently. 3. Increased Visibility and Credibility: Presenting at a prestigious event featuring clinical, investment, and industry opinion leaders enhances the company’s profile and credibility, attracting potential partners and building valuable industry connections. Apply to present today: https://bit.ly/4fmiRz0 #medtech #innovation #startups #InnovationDublin25

Robert Kennedy Jr., Dr. Oz, Marty Makary M.D., M.P.H., the Department of Government Efficiency, FDA, CMS, Congress, tariffs, and taxes were among the topics of conversation when Medical Device Manufacturers Association (MDMA)'s CEO Mark Leahey and AdvaMed CEO Scott Whitaker were on stage with us last month in San Diego at the MedTech Strategist Innovation Summit for a panel discussion about policy priorities in the wake of the US election. Health policy and regulation are heading for unpredictable times as the incoming Trump administration signals plans for major disruption. But that doesn’t portend disaster for the medtech sector and it could even open up some opportunities, according to the industry’s two top advocates in Washington, DC: https://bit.ly/4ilEylz #innovation #uselection #healthpolicy #regulation #medtech #medicaldevices

The three major cardiac rhythm management device companies are all taking slightly different approaches to developing pacemakers and implantable cardioverter defibrillators (ICDs) that, unlike traditional CRM devices, do not require a lead to run from the device generator through a vein and directly into the heart. Mike Matson, CFA, Analyst at Needham & Company: “The market for leadless devices is growing about 30% annually, as the overall $20-billion CRM market is growing in the low to mid-single digits.” Ken Stein, MD, Boston Scientific’s global chief medical officer: “We don't necessarily need to give everyone the device to do everything to treat every eventuality. We have the ability to start using multiple different types of devices in different patients as needs arise." Vish Charan, Leads product development for Abbott’s Cardiac Rhythm Management business: “[Aveir DR] is the first product ever brought to the market that you can insert and implant into the upper chamber and pace in the upper chamber of the heart in a synchronous manner … so that the two chambers of the heart remain in synchrony, which is extremely important to live a nice healthy life.” Robert Kowal, MD, PhD, Medtronic’s VP and general manager for Cardiac Pacing Therapies: “If the benefit [of leadless pacing] is about complication reduction, it has to be simple. And to be simple, it's got to be a single device that can do as much as possible.” Learn more here: https://bit.ly/4iSWvs3 #medicaldevices #innovation #medtech #ICD #CRM

Jupiter Endovascular’s Vertex Pulmonary Embolectomy System offers flexibility and precision. It tracks over a soft guidewire for gentle navigation through the right heart and pulmonary arteries. At the clot, hydrostatic pressure firms the device while conforming to anatomy, creating a stable base for deep aspiration. Unlike robotic systems, this manual technology provides unique adaptability. Jupiter Endovascular is running a US pivotal trial on a transcatheter device that can transform along its entire length from flexible for navigation to firm as a base of operation for therapy delivery. Its first application is the treatment of pulmonary embolism, an underpenetrated $3 billion market: https://bit.ly/4fi5wrw Source of image: Jupiter Endovascular #innovation #startups #medicaldevices #medicaltechnology #pulmonaryembolism

Are you a MedTech startup ready to transform patient care? Join the world’s largest accelerator for medical technology companies, dedicated to advancing human health. MedTech Innovator’s 4-month program offers: ✔ Top-tier mentoring & coaching ✔ Connections to investors & industry leaders ✔ Expert education via events & webinars ✔ Up to $800,000 in non-dilutive cash prizes Applications close 15 Jan 2025. Take your innovation to the next level! Apply now: https://lnkd.in/grVTCTv #medtech #medicaltechnology #innovation #startups